Author byline as per print journal: Michael Wilcock, MPhil; Andrew Pothecary, MSc
Introduction: Biological medicines are used to treat a range of conditions according to National Institute for Health and Care Excellence (NICE) technology appraisals. The annual drug treatment cost per patient per year varies depending on various factors, including newer or older biological, and availability of a biosimilar. Our biologicals pathway for dermatology (moderate or severe psoriasis) listed less expensive older biologicals (including biosimilars) early on in the treatment choices and more recently approved (and generally more expensive) choices lower down the pathway.
Submitted: 8 February 2021; Revised: 16 August 2021; Accepted: 26 August 2021; Published online first: 8 September 2021
Psoriasis, a common, chronic, non-communicable skin disease, affects at least 100 million individuals worldwide, and has great negative impact on patients’ quality of life . Initial psoriasis treatments include topical and systemic therapies, as well as phototherapy, and are designed to control only symptoms. Clearance of all skin lesions has become a realistic goal as a result of the introduction of a wide variety of biological drugs. The different biological drugs approved for use in moderate to severe psoriasis provide targeted inhibition of immune-mediated pathways involving specific cytokines, such as tumour necrosis factor (TNF) (e.g. etanercept, infliximab, adalimumab, and certolizumab pegol), interleukin (IL)-17 (e.g. secukinumab, ixekizumab, and brodalumab), and IL-23 (e.g. ustekinumab, guselkumab, tildrakizumab, and risankizumab).
This range of options of biologicals and oral treatments for moderate to severe psoriasis can be a challenge for clinicians, patients, and policymakers when deciding how the medicines compare in terms of efficacy and safety. There are a limited number of head-to-head trials even though network meta-analyses have been undertaken [2-5].
Across England and Wales, guidance from the National Institute for Health and Care Excellence (NICE) assesses the clinical and cost effectiveness of health technologies, including pharmaceuticals. The National Health Service (NHS) is legally obliged to fund and resource medicines and treatments recommended by NICE’s technology appraisals (TA). Furthermore, the NHS Constitution, which sets out rights to which patients, public and staff are entitled, and pledges which the NHS is committed to achieve, states that patients have the right to drugs and treatments that have been recommended by NICE for use in the NHS, if their doctor believes they are clinically appropriate . NICE’s guidance on psoriasis describes the various treatment options for psoriasis, identifying the relevant TA . The annual medicine acquisition cost to the NHS for treating a patient with moderate to severe psoriasis can range from approximately £3,000 to £13,000 depending on various factors, including availability of a biosimilar of the biological, e.g. for infliximab, etanercept, adalimumab, and whether there is a patient access scheme associated with the TA. A patient access scheme or commercial arrangement when associated with NICE guidance is a way in which pharmaceutical companies lower the acquisition cost of a medicine to the NHS to improve its cost-effectiveness, so enabling patients to gain access to high-cost medicine treatments. For instance, in the NICE TA for guselkumunab the discussion of the NICE committee focused on the cost comparison with ixekizumab and secukinumab and took into account all confidential patient access schemes, enabling the committee to conclude that the criteria for a positive cost comparison for guselkumunab were met . High-cost medicines are so named as they are expensive prescribed items, representing a disproportionate cost relative to the total NHS cost of the relevant hospital episode in terms of volume and cost.
Within England there have been a number of ongoing strategies to promote the use of biosimilars in hospitals including educational , setting of targets for the proportion of patients who are prescribed biosimilar choices of biologicals , and monitoring the local adoption of biosimilars by regional teams that facilitate implementation of national policy measures .
Our hospital is a 750-bed acute secondary care hospital in the south-west of England. The Dermatology Department developed a biologicals pathway which describes use of oral medicines, e.g. methotrexate or ciclosporin, and ultraviolet light therapy prior to the use of biologicals or selective immunosuppressants, e.g. apremilast, and then defaults to biosimilar adalimumab as first choice injectable treatment, see Flowchart 1.
Other biologicals may be chosen depending on various patient considerations. This pathway was approved by the health system-wide prescribing committee (composed of clinicians, pharmacists, and commissioners) in February 2019. Within Dermatology, patients considered for starting or switching biological treatment are discussed at a monthly multi-disciplinary team (MDT) meeting, attended by a hospital pharmacist.
The hospital, in conjunction with the local clinical commissioning group (CCG), utilizes the Blueteq high-cost drug management system. CCGs are statutory regional NHS bodies that are responsible for the planning and commissioning of healthcare services for their local area. Many CCGs in England use this Blueteq web-based system which allows clinicians to complete an online proforma for patients prescribed a high-cost medicine, such as a biological, and receive automatic approval for funding if the patient meets all the relevant criteria which normally reflect the NICE TA guidance. This ensures that clinicians receive the approval to treat immediately. The Blueteq system retains, as an audit trail, the request history, including patient name, drug, indication, criteria for use, date of request, requesting clinician, and whether the request was granted or not. This enables CCGs to monitor the use of expensive treatment, so that only treatments prescribed in line with NICE guidelines are reimbursed to the hospital
We aimed to identify which biologicals or selective immunosuppressants were used first line in adult patients with moderate or severe psoriasis, and ascertain the reasons for use of treatments other than adalimumab.
This was a retrospective, single site study. An extract was downloaded from the Blueteq system for a five-month period commencing November 2019 for adult patients granted approval to commence treatment for moderate to severe plaque psoriasis. This sample was chosen as a recent time period after allowing for a few months to pass since the guideline was approved in March 2019. Relevant data (patient demographics and treatment details) were imported into Excel by a member of the pharmacy team. The medical records of any patients commenced on treatments other than adalimumab were reviewed, and contact was made with the lead nurse in Dermatology if the records did not provide sufficient explanation for the treatment choice.
Health Research Authority criteria about research and service evaluation were considered. This was a retrospective assessment involving no changes to the service delivered to patients, and we used the NHS Health Research Authority tool (http://www.hradecisiontools.org.uk/research/index.html) which helped confirm that no ethical approval was required for this project. Patient data were used in accordance with local NHS hospital policy.
Over the five-month period, 33 patients (mean age 49 [range 20–82] years, 13 [39%] male) were commenced on one of the medicines of interest, see Table 1. Seventeen (52%) of these patients (mean age 49 [range 23–82] years, 9 [53%] male) were biological-naïve, whilst the remaining 16 were registered on Blueteq as they had switched from a prior biological therapy to a new therapy. Patients switching treatment were excluded as most had commenced their previous medicine prior to the introduction of the pathway.
Of the 17 biological-naïve patients, two commenced apremilast (as a biological was contraindicated), 10 commenced adalimumab, and five commenced other biologicals. Of these five, two were initiated on guselkumab, two on ustekinumab and one on certolizumab pegol. There was a documented reason in the medical records for choosing a biological other than adalimumab for two of these five patients and in the other three cases, the lead nurse in Dermatology was able to access other records to clarify the reason for the decision. These are summarized in Table 2.
This small-scale study found that the local guideline from early 2019 was followed as there were valid reasons for patients commencing treatments other than biosimilar adalimumab. Our agreed guideline is not overly prescriptive and deviation is allowed if the MDT agree that it is appropriate for the patient under discussion. The local guideline mirrors advice from national bodies in choice of certolizumab pegol in pregnancy [12, 13]. Guselkumab as first choice for palmoplantar pustulosis or specific body areas however was not explicitly supported by guidance that has emerged since the local guideline was produced [12, 13]. However, the NICE TA does state that evidence from clinical trials and indirect comparisons shows that guselkumab is more effective than TNF-alpha inhibitors, e.g. adalimumab . The evidence papers supporting this appraisal refer to the main comparison with adalimumab  noting that guselkumab showed superior clearance when used to treat regional psoriasis, such as scalp, finger nails, and hand and foot. The absolute differences for regional psoriasis outcomes favoured guselkumab by between 10% to 18%. The NICE TA at that time would not have considered the much lower cost to the NHS of a biosimilar adalimumab, and it is not clear from an incremental cost effectiveness viewpoint if patients with these hard-to-treat psoriatic areas should be treated with the less expensive biosimilar adalimumab first before moving on to guselkumab. Some studies do mention guselkumab as first choice based on small patient numbers [14, 15].
Overly prescriptive guidelines that require drugs to be used in a certain sequence with little scope for deviation may be good at controlling costs but may not be clinically appropriate as they do not allow for clinical judgement to over-ride the guideline where it is needed. If deviation from a guideline is tightly restricted this may increase demands on health services if patient’s needs are not adequately met, e.g. repeat clinic visits, poor mental health, comorbidity. The MDT approach allows for discussion of options with decisions reached by consensus not majority, helping to standardize practice across the specialty as decisions on treatment are no longer made by a single clinician. Involvement of nurses and pharmacist in the MDT allows consideration from different perspectives, and in our context the pharmacist is also involved with the Rheumatology team as well, which is useful when it comes to managing patients with psoriatic arthritis.
We recognize the limitations of a single centre, very small-scale study and that we do not report follow up of patients in relation to any improvement in their psoriasis. These results therefore cannot be generalized to other hospitals and to other indications for these classes of medicines.
A recent meta-analysis found that most biologicals cluster together with respect to short-term efficacy and tolerability, and the authors were unable to identify any single agent as ‘best’ . It is argued that the guideline resulting from this meta-analysis  and its linked evidence and decision aid will help the confused clinician make the best choices . We argue however that is it may be questionable if this guideline helps the health authority or commissioner payer as well. Hence, local future work should involve a review of our pathway, requiring the MDT decisions to be more explicit in their documentation, reviewing the initiation of biologicals over a longer time period, and possibly comparing pathways from different hospital Dermatology departments.
In this very small study, the choice of first-line biological for the treatment of moderate or severe psoriasis was in accordance with our local guideline in the majority of patients. Where deviation from the guideline occurred this was justified on clinical grounds, though documentation of these could be improved. These preliminary results from a very small sample size suggest the need for a larger study of the effectiveness of the guidelines over a longer period.
There were no funding sources.
Competing interest: None.
Provenance and peer review: Not commissioned; externally peer reviewed.
Michael Wilcock, MPhil
Andrew Pothecary, MSc
Royal Cornwall Hospitals NHS Trust, Truro, Cornwall TR1 3lJ, UK
1. WHO. Global report on psoriasis. Geneva: World Health Organization, 2016.
2. Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258-69. doi:10.1001/jamadermatol.2019.4029
3. Mrowietz U, Warren RB, Leonardi CL, Saure D, Petto H, Hartz S, et al. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index (PASI) values ≤1, 2, 3 or 5 derived from a statistical conversion method. J Eur Acad Dermatol Venereol. 2021;35(5):1161-75. doi:10.1111/jdv.17130
4. Wright E, Yasmeen N, Malottki K, Sawyer LM, Borg E, Schwenke C, et al. Assessing the quality and coherence of network meta-analyses of biologics in plaque psoriasis: what does all this evidence synthesis tell us? Dermatol Ther (Heidelb). 2021;11(1):181-220. doi:10.1007/s13555-020-00463-y
5. Mahil SK, Ezejimofor MC, Exton LS, Manounah L, Burden AD, Coates LC, et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta-analysis. Br J Dermatol. 2020;183(4):638-49. doi:10.1111/bjd.19325
6. National Institute for Health and Care Excellence. NICE technology appraisal guidance [homepage on the Internet]. [cited 2021 Aug 16]. Available from: https://www.nice.org.uk/About/What-we-do/Our-Programmes/NICE-
7. National Institute for Health and Care Excellence. Psoriasis: assessment and Management. Clinical Guideline 153. October 2012 [homepage on the Internet]. [cited 2021 Aug 16]. Available from: https://www.nice.org.uk/guidance/cg153/resources/psoriasis-assessment-and-management-pdf-35109629621701
8. National Institute for Health and Care Excellence. Guselkumab for treating moderate to severe plaque psoriasis. Technology appraisal guidance 521. June 2018 [homepage on the Internet]. [cited 2021 Aug 16]. Available from: https://www.nice.org.uk/guidance/ta521/resources/guselkumab-for-treating-moderate-to-severe-plaque-psoriasis-pdf-82606835435461
9. NHS England. What is a Biosimilar Medicine? 30 May 2019 [homepage on the Internet]. [cited 2021 Aug 16]. Available from: https://www.england.nhs.uk/publication/what-is-a-biosimilar-medicine/
10. NHS England. Commissioning framework for biological medicines (including biosimilar medicines) 2017 [homepage on the Internet]. [cited 2021 Aug 16]. Available from: https://www.england.nhs.uk/wp-content/uploads/2017/09/biosimilar-medicinescommissioning-framework.pdf
11. NHS England. Regional Medicines Optimisation Committees operating guidance and recruitment information. 20 April 2020 [homepage on the Internet]. [cited 2021 Aug 16]. Available from: https://www.england.nhs.uk/publication/ regional-medicines-optimisation-committee-operating-guidance-and-recruitment-information/
12. Smith CH, You ZZN, Bale T, Burden AD, Coates LC, Edwards W, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br J Dermatol. 2020;183(4):628-37. doi:10.1111/bjd.19039
13. Lambert JLW, Segaert S, Ghislain PD, Hillary T, Nikkels A, Willaert F, et al. Practical recommendations for systemic treatment in psoriasis according to age, pregnancy, metabolic syndrome, mental health, psoriasis subtype and treatment history (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 1). J Eur Acad Dermatol Venereol. 2020;34(8):1654-65. doi:10.1111/jdv.16684
14. Blauvelt A, Papp KA, Griffiths CE, Randazzo B, Wasfi Y, Shen YK, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo-and active comparator–controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405-17. doi:10.1016/j.jaad.2016.11.041
15. Wang WM, Jin HZ Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969-80. doi:10.1080/14740338.2020.1785427
16. Ormerod AD. Spoiled for choice? Are you confused by the number of biological options for psoriasis? Br J Dermatol. 2020;183(4):604. doi:10.1111/bjd.19401
Author for correspondence: Michael Wilcock, MPhil, Pharmacy Department, Royal Cornwall Hospitals NHS Trust, Truro, Cornwall TR1 3lJ, UK
Disclosure of Conflict of Interest Statement is available upon request.
Copyright © 2021 Pro Pharma Communications International
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.